NCT06723236View on ClinicalTrials.gov

A Study of MGC028 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

February 13, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2027

Conditions
Advanced Solid TumorsNSCLC AdenocarcinomaCholangiocarcinomaPancreatic CarcinomaColorectal Carcinoma
Interventions
BIOLOGICAL

MGC028

MGC028 is an antibody-drug conjugate targeted against ADAM9.

Trial Locations (6)

10029

RECRUITING

Icahn School of Medicine at Mt. Sinai, New York

49546

RECRUITING

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids

78229

RECRUITING

South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio

84119

RECRUITING

South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City

94115

RECRUITING

UCSF - Helen Diller Family Cancer Center, San Francisco

02115

RECRUITING

Dana Farber/Harvard Cancer Center, Boston

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
lead

MacroGenics

INDUSTRY

NCT06723236 - A Study of MGC028 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter